TABLE 2.
Plasma CMV DNA levels early after initiation of preemptive therapy and duration of episode of active CMV infection
| Episode of active CMV infection | DNAemia, median (range) no. of copies/ml, at time:
|
Episode duration, median (range) no. of days, determined by assay:
|
||
|---|---|---|---|---|
| Initiation of therapy | 1 wk (median) after therapy | PCR | Antigenemia | |
| Decreasing DNAemia (n = 23)a | 2,041 (33-99,898) | 111 (<25-3,078) | 21 (4-112) | 8 (2-100) |
| Increasing DNAemia (n = 12)b | 4,232 (288-169,487) | 11,727 (654-212,330) | 47 (17-570) | 35 (17-570) |
a
Decreasing CMV DNAemia levels at a median of 7 days (range, 3 to 10 days) after initiation of preemptive therapy.
b
Increasing CMV DNAemia levels at a median of 7 days (range, 3 to 20 days) after initiation of preemptive therapy. Dates of the last available positive sample were considered for the analysis of ongoing episodes (n = 5) at the end of the study period.